Gilde Healthcare leads USD 27 million financing round of innovative catheter company Inari Medical - Gilde Healthcare

Gilde Healthcare leads USD 27 million financing round of innovative catheter company Inari Medical

April 3, 2018

Irvine, US – Inari Medical, Inc., announced the close of a Series C financing totaling $27.0 million. The financing was led by new investor Gilde Healthcare and was joined by Versant Ventures and U.S. Venture Partners. Geoff Pardo of Gilde Healthcare will join Inari’s Board of Directors.

The financing provides Inari with capital to commercialize its innovative catheter-based technologies for the treatment of venous thromboembolism (“VTE”), a leading cause of death and disability worldwide affecting over 10 million patients annually. To date, Inari has developed the FlowTriever and ClotTriever Systems, both of which are designed to enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs.

“We are fortunate to have the support of a strong consortium of life sciences venture capital firms and would like to welcome both Gilde Healthcare as an investor in Inari and Geoff Pardo as a Board member,” said Bill Hoffman, President and Chief Executive Officer. “We will use these funds to support and accelerate our commercial, clinical and technology development programs.”

“There is a significant need to improve outcomes for the millions of patients suffering from VTE,” added Geoff Pardo of Gilde Healthcare. “We have been impressed by the Inari team, the progress they’ve made to date and their vision to transform the treatment of VTE.”

Ā 

About Inari Medical, Inc.

Inari Medical, Inc. is a privately held venture backed medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism (“VTE”). Inari is focused on solutions that enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs. Inari has developed two novel mechanical thrombectomy technology platforms, the FlowTriever and ClotTriever Systems.

Both Systems are 510(k) cleared by the U.S. FDA for thrombectomy in the peripheral vessels and have also received the CE mark. Inari was founded in 2013 as a spin-out of Inceptus Medical, a medical device incubator. The company is backed by Gilde Healthcare, Versant Ventures, U.S. Venture Partners, the founders, and other private investors. For more information, please visit www.inarimedical.com.

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Since 2001 Gilde Healthcare has raised EUR 800 million (USD 1 billion) for its specialized funds. Gilde is currently investing out of Gilde Healthcare IV which is financed, in part, by the European Recovery Program-European Investment Fund Facility. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

KariusĀ®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024